Business
Trevi Therapeutics to Participate in Upcoming Conferences
NEW HAVEN, Conn., May 9, 2024 /PRNewswire/ -- Trevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-stage biopharmaceutical company developing the
About this update from Trevi Therapeutics, Inc.
[{"type":"text","content":"NEW HAVEN, Conn., May 9, 2024 /PRNewswire/ -- Trevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-stage biopharmaceutical company developing the investigational therapy Haduvio™ (oral nalbuphine ER) for the treatment of chronic cough in idiopathic pulmonary fibrosis (IPF) and refractory chronic cough (RCC), today announced that senior management will be attending investor, business development and medical conferences in May and June.\n\n \n \n \n \n \n \n\n \nThe Citizens JMP Life Sciences ConferenceMay 13-14, 2024, New York, NY Corporate Presentation: May 14 at 12:00 p.m. ET Trevi Presenter: Jennifer Good, President and CEO\nATS 2024 International Conference May 17-22, 2024, San Diego, CA Session: A104: Advances in the Diagnosis and Treatment of ILD Abstract: Nalbuphine Extended-release Reduces Cough Bouts in Patients With Idiopathic Pulmonary Fibrosis Presentation: May 19, 3:00 p.m. - 4:15 p.m. PT Location: San Diego Convention Center, Room 33A-C (Upper Level) Presenter: Jacky Smith, MB, ChB, FRCP, PhD, Professor of Respiratory Medicine at the University of Manchester, and an Honorary Consultant at Manchester University NHS Foundation Trust. Director of the NIHR Manchester Clinical Research Facility, Respiratory Theme Lead in the NIHR Manchester Biomedical Research Centre and an NIHR Senior Investigator. \nRegistration details: https://conference.thoracic.org/ \nLife Science Education Series: Chronic Cough – KOL Panel DiscussionDiscussion: May 20, 12:30 p.m. - 2:30 p.m. PT Location: San Diego, CA Panel Members: Experts in the field of chronic cough include Professor Peter Dicpinigaitis, Professor Jacky Smith, and Professor Alyn Morice. Moderated by Oppenheimer's Senior Biotechnology Analyst Dr. Leland Gershell.\nTo register, email: [email protected]\n2024 BIO International ConventionJune 3-6, 2024, San Diego, CA\nOppenheimer's 2024 Montauk Life Sciences SummitJune 26-28, 2024, Montauk, NY\nAbout Trevi Therapeutics, Inc.Trevi Therapeutics, Inc. is a clinical-stage biopharmaceutical company developing the investigational therapy Haduvio™ (oral nalbuphine ER) for the treatment of chronic cough in idiopathic pulmonary fibrosis (IPF) and refractory chronic cough (RCC). Trevi is also developing Haduvio for prurigo nodularis. Haduvio is a dual ĸ-opioid receptor agonist and µ-opioid receptor antagonist that works both ce...